INDUSTRY BRIEF: Healthcare stocks under pressure as national drug list expands
Many Hong Kong-listed drugmakers on Monday announced their products that were included in the 2025 edition of China’s National Reimbursement Drug List (NRDL), which was unveiled this week. The updated…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
FAST NEWS: Four Sihuan affiliate products included in China’s national health plan
The latest: Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) announced Tuesday that four non-PVC solid-liquid double chamber bag products developed by its Beijing Ruiye affiliate have been included in the 2023 edition of…
FAST NEWS: Hutchmed swings to profit on strong revenue growth
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced Monday a net profit of $169 million in the first half of 2023, reversing a loss of $163 million in the same period…
FAST NEWS: Hutchmed, Zai Lab, Ascentage Drugs Land on China Reimbursement List
The latest: Products from Hutchmed (China) Ltd. (HCM.US; 0013.HK), Zai Lab Ltd. (ZLAB.US; 9688.HK) and Ascentage Pharma Group (6855.HK) were among 111 new drugs selected for new inclusion in the…
FAST NEWS: InnoCare Pharma Losses Double on Higher Costs And Exchange Deficit
The latest: InnoCare Pharma Ltd. (9969.HK) issued a profit warning Friday, estimating a net loss of no more than 495 million yuan ($73 million) for the first half of this year,…
FAST NEWS: InnoCare Pharma Granted Production Approval for Guangzhou Facility
The latest: InnoCare Pharma Ltd. (9969.HK) announced Monday its Guangzhou manufacturing facility has been approved by the China National Medical Products Administration (NMPA) to start the production of commercial supply of its…
Recent Articles
RELATED ARTICLES
-
Zai Lab under pressure over clinical results and rival drugs
9688.HKZLAB.US -
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
